22 Aug 2007
All images of bacteria in this post are taken, with author’s permission from Clinical Microbiological Reviews, published in 1997, 10(2), 320-344.
Gerald Domingue is a medical researcher and academic who served as Professor of Urology, Microbiology and Immunology in the Tulane University School of Medicine and Graduate School for thirty years and also as Director of Research in Urology. He is currently retired and resides in Zurich, Switzerland where he is engaged in painting and creative writing. At retirement he was honored with the title of Professor Emeritus at Tulane. Prior to Tulane, he served on the faculty of St. Louis University, was a lecturer at Washington University and director of clinical microbiology in St. Louis City Hospital, St. Louis, MO.
Over the course of his thirty-nine year career, Domingue received funding from the National Institutes of Health, Veterans Administration, and a variety of national and international research foundations. He enjoys international recognition as an authority on the basic biology and medical significance of atypical bacterial organisms and is considered an expert on the role of these bacteria in the persistence and expression of kidney and urological infectious diseases.
He first became interested in the role of atypical bacterial forms after noting that a large number of patients with urinary tract infections suffer from continual relapsing illness. Using a direct phase microscope, he examined the urine specimens of several patients with urinary tract infections and found L-form bacteria in his sample.
He began to investigate L-form bacteria, striving to better understand their biology and the role they play in causing disease. Over the course of the next 30 years, he was able to explain much of the mystery behind how the bacteria are able to persist in the body, and published a wide array of clinical and experimental studies on the subject.
Domingue worked with a team that included pre and post doctoral students and fellows along with faculty colleagues and laboratory assistants. Together they discovered that L-form bacteria are able to form tiny dense bodies within parent cells that already lack cell walls. They noted that the forms, which they called electron dense bodies were so small that they could pass through bacterial filters that normally withheld ordinary bacteria with cell walls.
The electron dense bodies could persist inside tissue culture cells in the laboratory. After applying this data to the human condition, Domingue reasoned that in some patients who suffer from chronic bacterial infections, the disease process could be related to the fact that bacteria are able to differentiate into the resistant electron dense bodies that he observed in tissue cultures.
In 1974, he and his graduate student, Mary Green, along with Paul Heidger, a faculty collaborator, published two landmark companion papers in the prestigious journal Infection and Immunity. The papers detail how L-form bacteria inside an experimental human embryonic kidney tissue culture system are able to persist in cells and explains how they are able to revert into the cell wall-containing parent bacterial form. They also proposed a detailed reproductive cycle for L-form bacteria, followed by electron microscopy of the microorganisms.
These papers set the stage for Domingue and his team to delve even further into the role that cryptic atypical bacteria play in causing persistent and recurrent infections.
In 1997, he and a colleague, the late Hannah Woody published an invited extensive review article on chronic bacterial infection in Clinical Microbiological Reviews. Among their conclusions was the claim that “difficult to culture and dormant bacteria are involved in the latency of infection and that these persistent bacteria may be pathogenic.”
He implicated L-form bacteria in several kidney-related diseases including pyelonephritis, glomerulonephritis, idiopathic hematuria, and interstitial cystitis. He also speculated about their role in other diseases such as rheumatic fever, tuberculosis, syphilis, and rheumatoid arthritis.
In the review Domingue stated, “Clearly, any patient with a history of recurrent infection and persistent disability is sending the signal that the phenomenon (infection with L-form bacteria) could be occurring. The so-called autoimmune diseases in which no organism can be identified by routine testing techniques are particularly suspect.”
He went on to conclude, “Bacteriologic advances, which include special culture media and stains, electron microscopy and molecular techniques such as PCR (polymerase chain reaction), have revealed an increasing number of previously unidentifiable organisms in a variety of pathologic conditions. It is unwise to dismiss the pathogenic capacities of any microbe in a patient with a mysterious disease.”
Over the course of his thirty-nine year career Domingue published 160 papers, monographs, and book chapters; 65 devoted to L-form research. He was invited to deliver over fifty international and national lectures about L-form bacteria and wrote a book on the subject, Cell Wall-Deficient Bacteria: Basic Principles and Clinical Significance. His papers are filled with photos of cultures of L-form bacteria taken with an electron microscope. They show the microbes inside human and animal cells.
Although Domingue’s primary research focused on bacterial L-forms, he also published extensively on the relationship between a molecule that stimulates the immune response called the Entobacterial Common Antigen (CA) and certain types of bacteria. He detailed the structure of the antigen and explained how it is able to elicit antibodies in humans and in animal models. He also detailed how the antigen could serve as a possible vaccine against urinary tract infections. He also studied the effects that a vasectomy might have on the immune system and performed studies on the relationship between the host and various species of bacteria in the disease pyelonephritis.
He delved into the effects of antibiotic therapy and chemotherapy on patients with urinary tract infections, and performed several studies on bacteria that produce a substance called chorionic gonadotropin-like hormone, detailing the way the bacteria might be involved in an experimental tumor model. He was even the co-author of a publication that characterized the oral microbial flora of alligators in order to develop better therapy for alligator bites.
When asked recently about his work Domingue replied, “I worked in a controversial research area for decades, and I found that sticking to the facts and hard data are the best ways to make progress in a field. Meaningful experimental designs and careful interpretation and discussion of the results are of prime importance in science. The ultimate aim was always to seek the truth about the problem at hand. Unfortunately, in the area of L-form or cell wall-defective bacteriology, too often there have been conclusions (anecdotal) drawn without supporting scientific data. In my opinion, many of these studies have hampered progress in the field and especially the role of these cryptic organisms in bacterial persistence and expression of disease. Sometimes the controversial issues have become political, which is unfortunate.
As far as I am concerned, modern technological tools are presently at hand to support all of the above microbiological and immunological findings at the molecular level… which is really what present day medical scientists, clinicians, pathologists are willing to accept as proof (maybe) of the role of such aberrant bacteria in disease.”
Indeed, molecular modeling has revealed how L-form bacteria are able to persist in the body and disable the immune system. Over the past few years, L-form bacteria have been linked to a wide array of chronic diseases, many of them previously considered to be autoimmune in nature. In 2002, biomedical researcher Trevor Marshall created a medical treatment that effectively kills L-form bacteria.
Now that L-form bacteria are known to cause a wide array of chronic inflammatory diseases, Domingue’s work is of utmost importance in allowing researchers to correctly demonstrate and understand their behavior.
Domingue, G., Lloyd, K., & Schlegel, J. U. (1974). In vitro phagocytosis of transitional phase bacterial variants utilizing autoradiography. Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.), 146(2), 635-42.
Domingue, G. J. (1980). Filterable cell-associated cryptic bacterial forms in immunologic renal diseases. Urological survey, 30(1), 1-4.
Domingue, G. J., Ghoniem, G. M., Bost, K. L., Fermin, C., & Human, L. G. (1995). Dormant microbes in interstitial cystitis. The Journal of urology, 153(4), 1321-6.
Domingue, G. J., & Schlegel, J. U. (1970). The possible role of microbial L-forms in pyelonephritis. The Journal of urology, 104(6), 790-8.
Domingue, G. J., & Schlegel, J. U. (1977). Novel bacterial structures in human blood: cultural isolation. Infection and immunity, 15(2), 621-7.
Domingue, G. J., & Schlegel, J. U. (1978). Novel bacterial structures in human blood. II. Bacterial variants as etiologic agents in idiopathic hematuria. The Journal of urology, 120(6), 708-11.
Domingue, G. J., Thomas, R., Walters, F., Serrano, A., & Heidger, P. M. (1993). Cell wall deficient bacteria as a cause of idiopathic hematuria. The Journal of urology, 150(2 Pt 1), 483-5.
Domingue, G. J., Woody, H. B., Farris, K. B., & Schlegel, J. U. (1979). Bacterial variants in urinary casts and renal epithelial cells. Archives of internal medicine, 139(12), 1355-60.
Domingue, G., & Woody, H. (1997). Bacterial persistence and expression of disease. Clin Microbiol Rev, 10(2), 320-344.
Domingue, G. J. (1982). Cell-wall Deficient Bacteria: Basic Principles and Clinical Significance. Reading, MA: Addison-Wesley Publishing Co.
Green, M. T., Heidger, P. M., & Domingue, G. (1974a). Demonstration of the phenomena of microbial persistence and reversion with bacterial L-forms in human embryonic kidney cells. Infection and immunity, 10(4), 889-914.
Green, M. T., Heidger, P. M., & Domingue, G. (1974b). Proposed reproductive cycle for a relatively stable L-phase variant of Streptococcus faecalis. Infection and immunity, 10(4), 915-27.
Ponig, B., Domingue, G., & Schlegel, J. (1972). The role of in vitro induced microbial L-forms in experimental hematogenous pyelonephritis. Investigative urology, 9(4), 282-5.
7 Responses for "Gerald Domingue: Pioneer of Atypical Bacteria"
Amy,
Great job on the website! I recommend anyone who is chronically ill to read this site and the Marshall Protocol website. Medicine and people who are ill with chronic diseases will never be the same thanks to Dr. Trevor Marshall and people like you who want to help others understand. Thanks for putting the science together in a concise easy to read format. Everyone, from patients to the medical profession need to know what causes chronic illness and how people with chronic illnesses can get their lives back.
Jeannine Jalanivich, RN
I highly appreciate the great achievements of Gerald Domingue in L-form research. His papers and book are always basic guidance in our experiments with L-forms. They are always citied in our L-form publications. We will be glad to contact him and to consult about interesting findings in this field, especially to know his opinion about “nanobacteria” and human blood L-form isolates.
I fully agree with his opinion about “ethics of scientific writing”.
Nadya Markova, PhD
Institute of Microbiology,
Bulgarian Academy of Sciences
Sofia, BULGARIA
Amy…………. The science is beyond me, but I know it’s a valuable thing that you are doing. I only wish it could somehow become a paying enterprise for you. You are amazing! Sharon Hamel
Just read some of the work. I am 39 years old, a school teacher who has struggled for 7 years with a mysterious diease. It’s been frustrating going through 5 seperate operations and all the tests you can imagine. I have three daughters and the will to get better. I lack the information. It would be really intersting to know if there is someone who could really help me. My new internal specialist has said that he could probably get me on a new research drug that is, if he can get my B-12 in check. I am on B-12 injections and other medications that I don’t think are helping me get better. They are just masking what the real culprit is. I have been diagnoised with fibromyalgia, endo, pernicious anemia and what ever else. I need help and someone to finish what they start. can you help?
Hi Joyce,
Your B12 injections and other medications are definitely just covering up your symptoms and not targeting what really making you sick. What is making you sick are different species of L-form bacteria, many of those which Domingue investigated.
The only treatment that will kill these bacteria and allow you to recover your health is the Marshall Protocol. In order to do the treatment, all you need to do is find a doctor who will prescribe you the necessary medications (antibiotics and Benicar). Then you work with him, but can also post your symptoms on the Marshall Protocol study site and you can be guided my experienced nurse moderators on how to best manage the immunopathology that results from taking the antibiotics.
Right now, what you should do is go to the following website:
http://www.curemyth1.org (Th1 disease is the name given to illnesses caused by L-form bacteria, hence the name Cure My Th1)
You an post all your questions about the Marshall Protocol - how to find a doctor, or how to work with your current doctor etc - on that site and they will be answered by patient advocates. They will guide you through the process of getting started.
You might want to take a look at the interview with Carole Morgan on this site. She was also a school teacher, also had fibromyalgia, and has gotten her life back thanks to the MP. The same will be true for you if you start the treatment.
http://bacteriality.com/2007/11/08/interview8/
Best,
Amy
Amy,
Just found this article through the MP website and found it very interesting and helpful. I’m so sick, I can hardly email, but wanted to thank you for the information you are making possible. I know it will help me cope. I am 64 and have been mostly “un-diagnosably” sick for 50+ years–particularly bad for the past 4-5 years. I’ve finally found a good doctor and will start the MP soon. Unfortunatly, my doctor prescribed Vit D 3 months ago before he discovered the MP, so I’m trying to get D levels back down now. It was 7 to start with, which seems now to be a good place for the MP, but now is 60! He’s fairly certain I have Lyme plus many other co-infections. Interesting about Pyelonephritis as I had a fairly bad case of it as a teenager and my brother lost a kidney to it. I have every symptom known to man and am now almost totally debilitated. Terribly depressed as I’m an active person in my heart and spirit and do not at all identify with being 64!
I haven’t posted on the MP site yet–just haven’t had the energy; but I will make myself do so very soon.
I’m looking forward to reading all else that you submitted.
Abigail
Hi Abigail,
Thanks so much for posting when I know it must be very draining for you. I’m so glad that you are working with your doctor to start the MP. It will take time, but in the end I’m convinced that your will get your life back and feel your age or even better.
There are many other people who started the MP in a very debilitated state and are making good progress. Plus, once you are on the MP there is usually a change in attitude. Instead of getting sicker each day, with every day spent on the MP you are getting a little bit better. As a friend used to tell me, “Once on the MP, every night you go to sleep with less bacteria then you did the day before.” From now on you will be headed in the right direction.
I know how hard it is to be an active and gregarious person, only to fall ill with a disease that prevents you from doing anything. I was young when I got sick, but became very ill very fast until I was completely bedridden - and just like you had symptoms in every single area of my body. I got very sick right during my last year of college and for a long time I was totally disconnected from other people and any sort of activity.
Now I am becoming more active and spending a great deal of time with family and friends. I never thought it would be possible before the MP.
Best,
Amy
Leave a reply